### TESTOMED ENAN 250 (testosterone enanthate) Injection
**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use TESTOMED ENAN 250 safely and effectively. See full prescribing information for TESTOMED ENAN 250.
TESTOMED ENAN 250 (testosterone enanthate) injection, for intramuscular use
**INDICATIONS AND USAGE**
TESTOMED ENAN 250 is a testosterone ester indicated for investigational use in promoting muscle growth, strength, and hormone replacement therapy in performance enhancement settings. Not approved for human therapeutic use in many jurisdictions; consult local regulations (1).
**DOSAGE AND ADMINISTRATION**
– Administer by deep intramuscular injection.
– Adult males: 250 mg to 750 mg per week, divided into one or two doses.
– Adult females: 50 mg to 150 mg per week, divided into one or two doses (2.1).
– Cycle duration: Typically 8 to 12 weeks.
**DOSAGE FORMS AND STRENGTHS**
Injection: 250 mg/mL in multi-dose vials (3).
**CONTRAINDICATIONS**
– Known or suspected carcinoma of the prostate or breast in males.
– Known or suspected carcinoma of the breast in females with hypercalcemia.
– Pregnancy (4).
– Hypersensitivity to testosterone enanthate, ethyl oleate, ricinus oil, or any component of the formulation (4).
**WARNINGS AND PRECAUTIONS**
– Cardiovascular risk: May alter lipid profiles; monitor cholesterol (5.1).
– Hepatotoxicity: Monitor liver function tests (5.2).
– Androgenic effects: Risk of virilization in females; discontinue if occurs (5.3).
– Suppression of endogenous testosterone: Use post-cycle therapy (5.4).
– Local reactions: Ethyl oleate or ricinus oil may cause injection site irritation (5.5).
**ADVERSE REACTIONS**
Common adverse reactions include acne, aggression, and injection site pain (6).
**DRUG INTERACTIONS**
– Anticoagulants: May enhance effects; monitor prothrombin time (7.1).
– Insulin or oral hypoglycemics: May alter glucose levels; adjust doses (7.2).
**USE IN SPECIFIC POPULATIONS**
– Pregnancy: Contraindicated (8.1).
– Lactation: Not recommended (8.2).
– Pediatric use: Not recommended; risk of premature epiphyseal closure (8.4).
– Geriatric use: Increased risk of prostate issues (8.5).
Revised: 08/2025
**FULL PRESCRIBING INFORMATION**
**1 INDICATIONS AND USAGE**
TESTOMED ENAN 250 is indicated for investigational use in adults to promote muscle mass and strength gains, enhance libido, improve energy and mood, increase red blood cell production, support recovery, enhance endurance, and stabilize hormone levels. It is commonly used in bulking cycles or as hormone replacement therapy in performance enhancement settings. This product is not approved for any medical condition and should be used under medical supervision.
**2 DOSAGE AND ADMINISTRATION**
**2.1 Recommended Dosage**
Administer TESTOMED ENAN 250 by deep intramuscular injection into the gluteal muscle or other large muscle groups. Rotate injection sites to minimize irritation.
– Males: 250 mg to 750 mg weekly, administered in one or two doses (e.g., weekly or biweekly).
– Females: 50 mg to 150 mg weekly, in one or two doses to minimize virilization risk.
Adjust dosage based on response and tolerance. Discontinue if adverse effects occur.
**2.2 Preparation and Handling**
Inspect vial for particulate matter or discoloration before use. Use sterile technique for administration.
**3 DOSAGE FORMS AND STRENGTHS**
TESTOMED ENAN 250 is supplied as a sterile solution containing 250 mg testosterone enanthate per mL in 10 mL multi-dose vials.
**4 CONTRAINDICATIONS**
TESTOMED ENAN 250 is contraindicated in:
– Patients with known or suspected prostate or breast carcinoma.
– Pregnant women (Category X).
– Patients with hypersensitivity to testosterone enanthate, ethyl oleate, ricinus oil, or other excipients.
– Patients with severe cardiac, hepatic, or renal insufficiency.
**5 WARNINGS AND PRECAUTIONS**
**5.1 Cardiovascular Effects**
May alter serum lipid profiles, increasing LDL and decreasing HDL, raising the risk of atherosclerosis. Monitor cholesterol levels periodically during treatment.
**5.2 Hepatotoxicity**
May cause elevated liver enzymes or, rarely, peliosis hepatis. Perform liver function tests before and during therapy; discontinue if jaundice or abnormal tests occur.
**5.3 Androgenic Effects**
Females may experience virilization, including deepening of voice, hirsutism, or clitoromegaly, which may be irreversible. Discontinue immediately if signs of virilization appear.
**5.4 Endocrine Effects**
Suppresses hypothalamic-pituitary-gonadal axis, reducing natural testosterone production. Implement post-cycle therapy to restore hormonal balance.
**5.5 Injection Site Reactions**
Ethyl oleate and ricinus oil may cause localized pain, redness, or swelling at the injection site. Rotate injection sites and monitor for signs of infection or abscess.
**6 ADVERSE REACTIONS**
Reported adverse reactions include:
– Dermatologic: Acne, oily skin, male pattern baldness in predisposed individuals.
– Psychiatric: Aggression, irritability, mood swings.
– Endocrine: Gynecomastia, testicular atrophy, reduced fertility.
– Cardiovascular: Hypertension, altered lipid profiles.
– Hepatic: Elevated AST/ALT, jaundice (rare).
– Local: Injection site pain, erythema, or abscess (rare).
**7 DRUG INTERACTIONS**
**7.1 Anticoagulants**
May increase bleeding risk with warfarin or other anticoagulants; monitor INR or prothrombin time closely.
**7.2 Hypoglycemic Agents**
May alter blood glucose levels, potentially requiring adjustment of insulin or oral antidiabetic doses; monitor closely.
**7.3 Corticosteroids**
Concurrent use may increase risk of edema, particularly in patients with cardiac or renal conditions.
**8 USE IN SPECIFIC POPULATIONS**
**8.1 Pregnancy**
Category X: May cause fetal harm, including virilization of a female fetus. Contraindicated in pregnant women.
**8.2 Lactation**
Excretion in breast milk is unknown; breastfeeding is not recommended due to potential risks to the infant.
**8.4 Pediatric Use**
Not recommended; may cause premature epiphyseal closure, leading to stunted growth.
**8.5 Geriatric Use**
Increased risk of prostatic hypertrophy or carcinoma; monitor prostate health closely during use.
**9 DRUG ABUSE AND DEPENDENCE**
Controlled substance in some jurisdictions. Potential for misuse leading to physical or psychological dependence, particularly with prolonged use or high doses.
**10 OVERDOSAGE**
Symptoms of overdose may include severe androgenic effects, such as aggression, acne exacerbation, or hypertension. No specific antidote exists; treat symptomatically and discontinue use immediately.
**11 DESCRIPTION**
TESTOMED ENAN 250 contains testosterone enanthate, a long-acting testosterone ester. It is a clear oily solution for intramuscular injection, with benzyl alcohol (1.5% v/v) as preservative, ethyl oleate, and ricinus oil (castor oil) as carrier oils. Half-life: Approximately 10 days.
**12 CLINICAL PHARMACOLOGY**
**12.1 Mechanism of Action**
Testosterone enanthate binds to androgen receptors, promoting protein synthesis, nitrogen retention, and red blood cell production for muscle growth and recovery.
**12.3 Pharmacokinetics**
Absorbed slowly after intramuscular injection; peak plasma levels in 2-3 days; half-life approximately 10 days; metabolized in the liver; excreted primarily in urine.
**13 NONCLINICAL TOXICOLOGY**
Animal studies indicate potential carcinogenicity, including hepatic and prostate tumors; no human data available.
**16 HOW SUPPLIED/STORAGE AND HANDLING**
10 mL multi-dose vial, 250 mg/mL. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Protect from light. Keep out of reach of children.
*Manufactured by: Medi Pharma*
